Cervical InsufficiencyNCT06822647
Optimal Timing of Routine Cervical Length Measurements During Anatomy Survey
A study testing Cervical Length Measurement at the Beginning of the Anatomy Survey and Cervical Length Measurement at the End of the Anatomy Survey in people with Cervical Insufficiency and Preterm Birth, run by Henry Ford Health System at 1 site in United States.
Trial summary
The goal of this clinical trial is to determine the optimal timing for measuring cervical length (CL) during fetal anatomy surveys in pregnant individuals. This study focuses on improving the accuracy of cervical length assessments, which are critical for identifying individuals at risk for preterm birth. Read more about this study
- Who is it for?
- Any age, women only
- Conditions the study is for
- Cervical Insufficiency, Preterm Birth, Cervical Length Measurement
- What is being tested?
- Cervical Length Measurement at the Beginning of the Anatomy Survey and Cervical Length Measurement at the End of the Anatomy Survey
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 550 participants
- Where
- 1 siteUnited States
- Study dates
- 20 Jan 2025to 1 Jul 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Pregnant individuals between 16 weeks and 23 weeks + 6 days of gestation.
- Presenting for a fetal anatomy survey at Henry Ford Health MFM ultrasound units.
- Consent to a transvaginal cervical length measurement as part of routine care.
- Agreement to participate in the study, including randomization for the timing of cervical length measurement.
Who cannot join
- History of preterm delivery.
- Diagnosis of cervical insufficiency.
- Declines or unable to consent to a transvaginal cervical length measurement.
- Patients receiving care at non-Henry Ford Health radiology clinics.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Henry Ford Health New Center One
Detroit, Michigan, 48202
Shelby Masters, MD, 313-671-5225, smaster1@hfhs.org
Raminder Khangura, MD
About this study
The goal of this clinical trial is to determine the optimal timing for measuring cervical length (CL) during fetal anatomy surveys in pregnant individuals. This study focuses on improving the accuracy of cervical length assessments, which are critical for identifying individuals at risk for preterm birth. The main questions it aims to answer are:
- Does measuring cervical length at the beginning of the anatomy survey result in a higher proportion of scans meeting the nine CLEAR (Cervical Length Education and Review) criteria compared to measuring at the end of the survey?
- Does the use of sepia-filtered ultrasound images improve the proportion of scans meeting the nine CLEAR criteria compared to conventional grayscale images?
Read more
Researchers will compare two groups of participants randomized to have cervical length measured either at the beginning or at the end of the anatomy survey. Additionally, all participants will undergo cervical length measurements using both grayscale and sepia-filtered ultrasound imaging.
Participants will:
- Receive a patient information sheet through MyChart explaining the study and standard cervical length screening during anatomy surveys.
- Provide verbal consent for a transvaginal ultrasound and study participation.
- Be randomized to have their cervical length measured at either the start or end of the fetal survey.
- Undergo cervical length measurement using both grayscale and sepia-filtered ultrasound imaging modalities.
- This study involves no additional risks beyond those of routine clinical care and aims to enhance clinical practice by identifying optimal methods for cervical length assessment during pregnancy.
Read the detailed description
Study Title: Optimal Timing of Routine Cervical Length Measurements During Anatomy Survey
Study Aim and Background: This randomized controlled trial investigates whether the timing of cervical length measurements during fetal anatomy surveys impacts the accuracy of assessments. Current guidelines recommend transvaginal cervical length screening during anatomy surveys to identify individuals at risk for preterm birth. However, the guidelines do not specify whether measurements should be taken at the beginning or end of the ultrasound exam, a lengthy procedure (60-90 minutes) that may introduce uterine contractions and distort results. Additionally, the study evaluates whether using sepia-filtered ultrasound images can enhance measurement accuracy compared to conventional grayscale imaging.
Primary Hypothesis: Cervical lengths measured at the beginning of the fetal survey will result in a higher proportion of scans meeting the nine CLEAR criteria than those measured at the end.
Secondary Hypothesis: Sepia-filtered ultrasound imaging will yield a greater proportion of scans meeting the CLEAR criteria compared to grayscale imaging.
Study Design:
- Type: Randomized controlled trial.
- Setting: Conducted across all Maternal Fetal Medicine (MFM) ultrasound units within Henry Ford Health (HFH).
- Population: Pregnant individuals between 16w0d and 23w6d gestation undergoing fetal anatomy surveys. Participants with a history of preterm birth or cervical insufficiency are excluded.
- Intervention: Randomization of participants to have cervical length measurements taken at either the beginning or end of the anatomy survey. Measurements will be performed using both grayscale and sepia-filtered imaging modalities.
- Randomization: Pre-prepared envelopes (n=550) direct sonographers to perform cervical length measurement either at the start or end of the anatomy survey. Envelopes are indistinguishable and shuffled to ensure blinding.
Procedures:
Patient Enrollment:
- Prior to the anatomy scan, participants receive a MyChart information sheet outlining the study.
- Participants provide verbal consent for cervical length measurement via transvaginal ultrasound and for study participation.
- Verbal consent is documented in the patient's chart.
Randomization:
- Upon consent, the sonographer randomly selects an envelope to determine the timing of cervical length measurement.
- Cervical length measurements are conducted per routine care, ensuring the bladder is emptied beforehand.
Data Collection:
- Cervical length is measured using both grayscale and sepia-filtered ultrasound images.
- Sonographers save the first image with the word "CLEAR" to indicate study participation.
- MFM physicians complete a worksheet assessing the nine CLEAR criteria for each scan. These worksheets are de-identified and stored securely in a binder.
Data Security:
- Worksheets containing study data are stored in a secure MFM physician workroom, accessible only via HFH badge access.
- De-identified data is entered into a secure database, password-protected and accessible only to authorized personnel. The database will be erased following data analysis and publication.
Analysis Plan:
- Primary Analysis: Proportion of scans meeting the nine CLEAR criteria will be compared between groups (cervical length measured at beginning vs. end of survey) using chi-square tests. Logistic regression will adjust for confounders such as gestational age and sonographer experience.
- Secondary Analysis: Effect of sepia-filtered imaging on CLEAR criteria adherence will be evaluated using paired t-tests or Wilcoxon signed-rank tests. Interaction analysis will assess the combined effects of timing and imaging modality using two-way ANOVA or logistic regression.
- Handling Missing Data: Multiple imputation techniques will address missing values in the CLEAR criteria.
- Sample Size: A total of 550 participants (275 per group) provides 80% power to detect a 10-15% difference in the proportion of scans meeting the CLEAR criteria, assuming a baseline adherence of 60%.
Anticipated Risks and Benefits:
- Risks: No additional risks beyond standard cervical length screening.
- Benefits: Improved accuracy in cervical length measurements could optimize clinical decision-making and patient outcomes, particularly for managing short cervix during pregnancy.
Confidentiality:
- No personally identifiable information (PHI) is linked to study worksheets or data.
- IRB-approved procedures ensure confidentiality and data integrity.
Investigator Qualifications:
- Primary Author: Shelby Masters, MD, MFM Fellow.
- Principal Investigator: Raminder Khangura, MD, MFM Attending.
- Co-Investigators: Nicolina Smith, DO, and Shahd Karrar, MD, MFM Fellows.
This innovative study, which has not been explored previously in the literature, has the potential to influence clinical guidelines for cervical length measurement during pregnancy, ensuring more reliable assessments and improved care for at-risk patients.
- Being tested
- Cervical Length Measurement at the Beginning of the Anatomy Survey, Cervical Length Measurement at the End of the Anatomy Survey
- Medical subject headings
- Uterine Cervical Incompetence, Premature Birth
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cervical Length Measurement at the Beginning of the Anatomy SurveyProcedure or surgery
This intervention involves performing a transvaginal ultrasound to measure cervical length at the beginning of the fetal anatomy survey. The procedure includes using both grayscale and sepia-filtered imaging to evaluate adherence to the nine CLEAR criteria for accurate cervical length assessment.
Cervical Length Measurement at the End of the Anatomy SurveyProcedure or surgery
This intervention involves performing a transvaginal ultrasound to measure cervical length at the end of the fetal anatomy survey. The procedure includes using both grayscale and sepia-filtered imaging to evaluate adherence to the nine CLEAR criteria for accurate cervical length assessment.
| Study group | Role | What they receive |
|---|---|---|
| Beginning of Anatomy Survey | Experimental | Participants in this arm will undergo cervical length measurement via transvaginal ultrasound at the start of the fetal anatomy survey. This timing aims to evaluate whether early measurement improves adherence to the nine CLEAR criteria for accurate cervical length assessment. Measurements will also be conducted using grayscale and sepia-filtered ultrasound imaging. Receives: Procedure: Cervical Length Measurement at the Beginning of the Anatomy Survey |
| End of Anatomy Survey | Experimental | Participants in this arm will undergo cervical length measurement via transvaginal ultrasound at the end of the fetal anatomy survey. This timing aims to evaluate whether late measurement improves adherence to the nine CLEAR criteria for accurate cervical length assessment. Measurements will also be conducted using grayscale and sepia-filtered ultrasound imaging. Receives: Procedure: Cervical Length Measurement at the End of the Anatomy Survey |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of Cervical Length Measurements Meeting CLEAR Criteria at time of anatomy scan, between 18-24 weeks gestation, measured by transvaginal ultrasound
The primary outcome is the proportion of transvaginal cervical length measurements that meet all nine CLEAR (Cervical Length Education and Review) criteria for accuracy. This will assess whether timing (beginning vs. end of anatomy survey) impacts measurement reliability.
Measured: At the time of the fetal anatomy survey, specifically 18-24wks (one-time measurement per participant).
Secondary outcomes (1)
Proportion of Scans Meeting CLEAR Criteria Using Sepia-Filtered Imaging
The secondary outcome evaluates whether sepia-filtered ultrasound imaging improves adherence to the nine CLEAR criteria compared to conventional grayscale imaging. Measurements will be analyzed for both imaging modalities.
Measured: At the time of the fetal anatomy survey, specifically 18-24wks (one-time measurement per participant).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Feb 2025
- Study start20 Jan 2025
- Primary completion1 Jun 2027 (estimated)
- Study completion1 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cervical InsufficiencyStudies of the same condition, open and under way.
- More trials run by Henry Ford Health SystemThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants are randomized to have cervical length measurements taken either at the beginning or the end of the anatomy survey.
- Masking
- None (open label)
- Enrolment
- 550 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Henry Ford Health System
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Raminder Khangura, Henry Ford Health System
- Investigators
- Raminder Khangura, MD, Principal investigator, Henry Ford Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06822647
- Sponsor's protocol ID
- 16839
- Status last verified
- Mar 2026
- First submitted
- 29 Jan 2025
- Last updated
- 9 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Optimal Timing of Routine Cervical Length Measurements During Anatomy Survey
- ClinicalTrials.gov ID
- NCT06822647
- Acronym / sponsor ID
- 16839
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 550 participants (estimated)
- Lead sponsor
- Henry Ford Health SystemUniversity, hospital or other
- Study start
- 20 Jan 2025 (actual)
- Primary completion
- 1 Jun 2027 (estimated)
- Study completion
- 1 Jul 2027 (estimated)
- First posted
- 12 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to determine the optimal timing for measuring cervical length (CL) during fetal anatomy surveys in pregnant individuals. This study focuses on improving the accuracy of cervical length assessments, which are critical for identifying individuals at risk for preterm birth. The main questions it aims to answer are:
- Does measuring cervical length at the beginning of the anatomy survey result in a higher proportion of scans meeting the nine CLEAR (Cervical Length Education and Review) criteria compared to measuring at the end of the survey?
- Does the use of sepia-filtered ultrasound images improve the proportion of scans meeting the nine CLEAR criteria compared to conventional grayscale images?
Researchers will compare two groups of participants randomized to have cervical length measured either at the beginning or at the end of the anatomy survey. Additionally, all participants will undergo cervical length measurements using both grayscale and sepia-filtered ultrasound imaging.
Participants will:
- Receive a patient information sheet through MyChart explaining the study and standard cervical length screening during anatomy surveys.
- Provide verbal consent for a transvaginal ultrasound and study participation.
- Be randomized to have their cervical length measured at either the start or end of the fetal survey.
- Undergo cervical length measurement using both grayscale and sepia-filtered ultrasound imaging modalities.
- This study involves no additional risks beyond those of routine clinical care and aims to enhance clinical practice by identifying optimal methods for cervical length assessment during pregnancy.
Detailed description
Study Title: Optimal Timing of Routine Cervical Length Measurements During Anatomy Survey
Study Aim and Background: This randomized controlled trial investigates whether the timing of cervical length measurements during fetal anatomy surveys impacts the accuracy of assessments. Current guidelines recommend transvaginal cervical length screening during anatomy surveys to identify individuals at risk for preterm birth. However, the guidelines do not specify whether measurements should be taken at the beginning or end of the ultrasound exam, a lengthy procedure (60-90 minutes) that may introduce uterine contractions and distort results. Additionally, the study evaluates whether using sepia-filtered ultrasound images can enhance measurement accuracy compared to conventional grayscale imaging.
Primary Hypothesis: Cervical lengths measured at the beginning of the fetal survey will result in a higher proportion of scans meeting the nine CLEAR criteria than those measured at the end.
Secondary Hypothesis: Sepia-filtered ultrasound imaging will yield a greater proportion of scans meeting the CLEAR criteria compared to grayscale imaging.
Study Design:
- Type: Randomized controlled trial.
- Setting: Conducted across all Maternal Fetal Medicine (MFM) ultrasound units within Henry Ford Health (HFH).
- Population: Pregnant individuals between 16w0d and 23w6d gestation undergoing fetal anatomy surveys. Participants with a history of preterm birth or cervical insufficiency are excluded.
- Intervention: Randomization of participants to have cervical length measurements taken at either the beginning or end of the anatomy survey. Measurements will be performed using both grayscale and sepia-filtered imaging modalities.
- Randomization: Pre-prepared envelopes (n=550) direct sonographers to perform cervical length measurement either at the start or end of the anatomy survey. Envelopes are indistinguishable and shuffled to ensure blinding.
Procedures:
Patient Enrollment:
- Prior to the anatomy scan, participants receive a MyChart information sheet outlining the study.
- Participants provide verbal consent for cervical length measurement via transvaginal ultrasound and for study participation.
- Verbal consent is documented in the patient's chart.
Randomization:
- Upon consent, the sonographer randomly selects an envelope to determine the timing of cervical length measurement.
- Cervical length measurements are conducted per routine care, ensuring the bladder is emptied beforehand.
Data Collection:
- Cervical length is measured using both grayscale and sepia-filtered ultrasound images.
- Sonographers save the first image with the word "CLEAR" to indicate study participation.
- MFM physicians complete a worksheet assessing the nine CLEAR criteria for each scan. These worksheets are de-identified and stored securely in a binder.
Data Security:
- Worksheets containing study data are stored in a secure MFM physician workroom, accessible only via HFH badge access.
- De-identified data is entered into a secure database, password-protected and accessible only to authorized personnel. The database will be erased following data analysis and publication.
Analysis Plan:
- Primary Analysis: Proportion of scans meeting the nine CLEAR criteria will be compared between groups (cervical length measured at beginning vs. end of survey) using chi-square tests. Logistic regression will adjust for confounders such as gestational age and sonographer experience.
- Secondary Analysis: Effect of sepia-filtered imaging on CLEAR criteria adherence will be evaluated using paired t-tests or Wilcoxon signed-rank tests. Interaction analysis will assess the combined effects of timing and imaging modality using two-way ANOVA or logistic regression.
- Handling Missing Data: Multiple imputation techniques will address missing values in the CLEAR criteria.
- Sample Size: A total of 550 participants (275 per group) provides 80% power to detect a 10-15% difference in the proportion of scans meeting the CLEAR criteria, assuming a baseline adherence of 60%.
Anticipated Risks and Benefits:
- Risks: No additional risks beyond standard cervical length screening.
- Benefits: Improved accuracy in cervical length measurements could optimize clinical decision-making and patient outcomes, particularly for managing short cervix during pregnancy.
Confidentiality:
- No personally identifiable information (PHI) is linked to study worksheets or data.
- IRB-approved procedures ensure confidentiality and data integrity.
Investigator Qualifications:
- Primary Author: Shelby Masters, MD, MFM Fellow.
- Principal Investigator: Raminder Khangura, MD, MFM Attending.
- Co-Investigators: Nicolina Smith, DO, and Shahd Karrar, MD, MFM Fellows.
This innovative study, which has not been explored previously in the literature, has the potential to influence clinical guidelines for cervical length measurement during pregnancy, ensuring more reliable assessments and improved care for at-risk patients.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Participants are randomized to have cervical length measurements taken either at the beginning or the end of the anatomy survey.
| Arm | Type | Receives |
|---|---|---|
| Beginning of Anatomy Survey | Experimental | Procedure: Cervical Length Measurement at the Beginning of the Anatomy SurveyParticipants in this arm will undergo cervical length measurement via transvaginal ultrasound at the start of the fetal anatomy survey. This timing aims to evaluate whether early measurement improves adherence to the nine CLEAR criteria for accurate cervical length assessment. Measurements will also be conducted using grayscale and sepia-filtered ultrasound imaging. |
| End of Anatomy Survey | Experimental | Procedure: Cervical Length Measurement at the End of the Anatomy SurveyParticipants in this arm will undergo cervical length measurement via transvaginal ultrasound at the end of the fetal anatomy survey. This timing aims to evaluate whether late measurement improves adherence to the nine CLEAR criteria for accurate cervical length assessment. Measurements will also be conducted using grayscale and sepia-filtered ultrasound imaging. |
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (4 listed)
- Pregnant individuals between 16 weeks and 23 weeks + 6 days of gestation.
- Presenting for a fetal anatomy survey at Henry Ford Health MFM ultrasound units.
- Consent to a transvaginal cervical length measurement as part of routine care.
- Agreement to participate in the study, including randomization for the timing of cervical length measurement.
Key exclusion criteria (4 listed)
- History of preterm delivery.
- Diagnosis of cervical insufficiency.
- Declines or unable to consent to a transvaginal cervical length measurement.
- Patients receiving care at non-Henry Ford Health radiology clinics.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cervical Length Measurement at the Beginning of the Anatomy SurveyThis intervention involves performing a transvaginal ultrasound to measure cervical length at the beginning of the fetal anatomy survey. The procedure includes using both grayscale and sepia-filtered imaging to evaluate adherence to the nine CLEAR criteria for accurate cervical length assessment. | Procedure or surgery | Beginning of Anatomy Survey |
| Cervical Length Measurement at the End of the Anatomy SurveyThis intervention involves performing a transvaginal ultrasound to measure cervical length at the end of the fetal anatomy survey. The procedure includes using both grayscale and sepia-filtered imaging to evaluate adherence to the nine CLEAR criteria for accurate cervical length assessment. | Procedure or surgery | End of Anatomy Survey |
Primary outcome
Proportion of Cervical Length Measurements Meeting CLEAR Criteria at time of anatomy scan, between 18-24 weeks gestation, measured by transvaginal ultrasound
Time frame: At the time of the fetal anatomy survey, specifically 18-24wks (one-time measurement per participant).
The primary outcome is the proportion of transvaginal cervical length measurements that meet all nine CLEAR (Cervical Length Education and Review) criteria for accuracy. This will assess whether timing (beginning vs. end of anatomy survey) impacts measurement reliability.
1 secondary outcome
Proportion of Scans Meeting CLEAR Criteria Using Sepia-Filtered Imaging
Time frame: At the time of the fetal anatomy survey, specifically 18-24wks (one-time measurement per participant).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Mar 2026.
Related trials for Cervical Insufficiency
Not yet recruitingObservational study
Cervical Length Reference Range at 28-34 Weeks in Singleton Pregnancies
Preterm Birth, Cervical Length
Not yet recruitingPhase 4
Azithromycin for Cerclage Prophylaxis
Cervical Insufficiency
Not yet recruiting
Personalized Care for Prenatal Stress Reduction & Prevention of Preterm Birth (PTB) Disparities
Preterm Birth Complication, Preterm Birth
RecruitingEarly Phase 1
Concomitant Renal and Urinary Bladder Allograft Transplantation
Chronic Kidney Diseases, Bladder Dysfunction
Active, not recruitingPhase 1
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Breast Carcinoma, Carcinoma of Unknown Primary
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Raminder Khangura, MD principal investigator
Henry Ford Health
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cervical Length Measurement at the Beginning of the Anatomy Survey and Cervical Length Measurement at the End of the Anatomy Survey in people with Cervical Insufficiency and Preterm Birth, run by Henry Ford Health System at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Shelby A Masters, MD (313-671-5225, smaster1@hfhs.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of Cervical Length Measurements Meeting CLEAR Criteria at time of anatomy scan, between 18-24 weeks gestation, measured by transvaginal ultrasound (time frame: At the time of the fetal anatomy survey, specifically 18-24wks (one-time measurement per participant).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Mar 2026.